EB-DuoNK-MSLN/HER2 cell therapy (Beijing Biotech)

N/A

Report date: 2026/03/13 20:02:36

Base Information

Drug NameEB-DuoNK-MSLN/HER2 cell therapy (Beijing Biotech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsMesothelin modulatorsReceptor protein-tyrosine kinase erbB-2 modulators

TargetsMesothelinReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesBeijing Biotech

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A